Skip to main content

Advertisement

Table 4 Immunotherapy trials addressing thyroid cancer

From: Novel targeted therapies and immunotherapy for advanced thyroid cancers

Immunological Target Trial Brief description
TAM NCT01346358 CSF-1R antibody LY3022855 (also known as IMC-CS4) is tested in advanced solid tumors, including thyroid cancer
TAM NCT01525602 Testing the effect of CSF-1R inhibitor (PLX3397) plus paclitaxel in patients with advanced solid tumors, including thyroid cancer
Dendritic cells NCT01856920 Testing GI-6207, a vaccine made from baker’s yeast, targeting the CEA in patients with MTC
Dendritic cells NCT02239861 Testing specific adoptive cytotoxic T cells targeting several tumor antigens (NY-ESO-1, MAGEA4, PRAME, survivin, and SSX) in patients with advanced solid tumors, including thyroid cancer patients
T cells NCT02054806 Testing Pembrolizumab effect as monotherapy in advanced solid tumor patients, including a cohort of thyroid cancer patients
TAM NCT02452424 Testing CSF-1R inhibitor (PLX3397) plus PD-1 inhibitor (Pembrolizumab) against advanced melanoma and other solid tumors, including thyroid
TAM NCT02718911 Testing another CSF-1R inhibitor (LY3022855) plus Tremelimumab or Durvalumab (PD-1 inhibitors) in solid tumors
  NCT02614495 Open label - two cohorts - phase I, II trial assessing the role of Sulfatinib in advanced MTC and RAI-R DTC
T cells NCT02501096 Phase IB/II trial, currently recruiting patients with solid tumors to assess the maximum tolerated dose (MTD) for Lenvatinib in combination with Pembrolizumab during phase IB of the trial. A subsequent expansion phase II trial will evaluate the safety and efficacy of this combination
T cells NCT01988896 Testing the effect of combining the PDL-1 inhibitor Atezolizumab, plus the mitogen-activated protein kinase (MAPK) inhibitor, Cobimetinib, in Locally Advanced or Metastatic Solid Tumors
T cells NCT01656642 Phase IB trial investigating PD-L1 antibody Atezolizumab plus mutant BRAF inhibitor Vemurafenib for patients with BRAFV600 mutation-positive metastatic melanoma (even though this trial has no thyroid patients, its results will help in designing future thyroid trials using such a combination based on pharmacodynamics and kinetics of this study)